Patented Medicine Prices Review Board

Patented Medicine Prices Review Board

March 27, 2007 16:00 ET

The PMPRB to Hold a Public Hearing Into the Price of Penlac Nail Lacquer

OTTAWA, ONTARIO--(CCNMatthews - March 27, 2007) - The Patented Medicine Prices Review Board will hold a public hearing commencing on July 23, 2007, in the matter of sanofi-aventis Canada Inc. ("Sanofi-Aventis") and the price of the medicine Penlac Nail Lacquer ("Penlac"). A pre-hearing conference will also be held on June 6, 2007.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the Patent Act, Sanofi-Aventis

- is selling or has sold the medicine known as "Penlac" in any market in Canada at a price that, in the Board's opinion, is or was excessive; and,

- if so, what order, if any, should be made.

Penlac is a new formulation of an existing compound (ciclopirox). It is a topical medicine indicated for fungal nail infections. Penlac is indicated as part of a comprehensive nail management program in immunocompetent patients with mild to moderate onychomycosis (due to Trichophyton rubrum) of fingernails and toenails without lunula involvement.

Persons wishing to intervene in this proceeding are required to apply to the Board for leave to intervene on or before April 23, 2007. Such persons should contact the Secretary of the Board for further information on the procedure.

The Notice of Hearing in this matter and the Statement of Allegations of Board Staff are available on the PMPRB Web site under Regulatory, Hearings.

All requests for information should be addressed to the Secretary of the Board.

Contact Information